Virtual Network's Login.
ESH Gold Institutional Partner
ESH Gold Institutional Partner
| Friday, September 11, 2009 | ||
| 08h00-08h05 | Opening session |
J. Reiffers (Bordeaux) |
| 08h05-08h10 | Welcome and introduction | J. Goldman (London) |
| 08h10-08h40 | ICMLF Inaugural Lecture - Chairs: J. Reiffers (Bordeaux) and J.Goldman (London) |
|
| 08h10-08h40 | TKIs now but what next? | B. Druker (Portland) |
| Sessiom 1 |
Activated kinases in MPDs - Chair: P. Laneuville (Montreal) |
|
| 08h40-08h55 |
TET2 alterations in the multistep onset of myeloproliferative disorders |
F. Delhommeau (Paris) |
| 08h55-09h05 | Structural positioning of the SH2 domain is critical in BCR- ABL leukemogenesis |
O. Hantschel (Vienna) |
| 09h05-09h15 | Point mutations in PDGF RA in myeloproliferative disease | S. Koschmieder (Muenster) |
| 09h15-09h25 | Jak2 regulates Bcr-Abl signaling | R. Arlinghaus (Houston) |
| 09h25-09h40 | Discussion | |
| Session 2 | Molecular events in CP - Chair: P. Valent (Vienna) | |
| 09h40 - 11h20 |
Which molecular events are really "initiating?" |
M. Deininger (Portalnd)) |
| 09h55-10h05 | Th Myb gne in leukemogenesis | A. Gewirtz (Philadelphia) |
| 10h05-10h15 | CHIP works with Hsc-70 co-chaperone to degrade BCR-ABL | Y. Maru (Tokyo) |
| 10h15-10h25 | Wnt-β-catenin signalling | A. Abrahamsson (San Diego) |
| 10h25-10h35 | Blockage of GSK3b promotes sensitivity of Ph+LSC to Bcr-Abl inhibition | G. Gambacorti (Monza) |
| 10h35-10h45 | Reactivation of PP2A inhibits self renewal in CD34+ CML cells | D. Perrotti (Columbus) |
| 10h45-10h55 |
Involvement of FANCD2 in BCR-ABL mediated transformation |
T. Stoklosa (Philadelphia) |
| Discussion | ||
| 11h20 - 11h40 | Break |
|
| Session 3 |
Molecular events in advanced phase - Chair: J. Griffin (Boston) |
|
| 11h40 - 12h50 |
Which molecular events really underlie progression? |
D. Perrotti (Columbus) |
| 11h55-12.05 | Loss of miR-328 may promotes progression from CP to AP | A. Eiring (Columbus) |
| 12h05-12h15 |
Ph-neg high risk ALL resembling Ph+ ALL |
C. Mullighan (Memphis) |
| 12h15-12h25 | Whole genome sequencing of Ph-positive ALL | I. Iacobucci (Bologna) |
| 12h25-12h35 | BCR and BCR-ABL regulation during myeloid differentiation in CML and normal persons | M. Marega (Monza) |
| Discussion | ||
| 12h50 - 14h15 |
Buffet luch and poster viewing |
|
| Session 4 14h15 - 15h15 |
Panel and Poster discussion (1) - Chair: J. Radich (Seattle) Selected topics from posters |
|
| ROS and reactive nitrogen species in CML | E. Bolton (Philadelphia) | |
| Rac'n Roll and Not Rock'n Roll: A new RhoA pathway to trigger amoeboid motily | N. Bourmeyster (Poitiers) | |
| Functional p53 is required for effective telomerase inhibition in BCR-ABL positive CML cell's | T. Brummendorf (Aachen) | |
| Computational and experimental characterization of two nuclear localizaton signals and a nuclear export signal that may modulate BCR intracellular localization | A. Fiddio (Catania) | |
| Sts-1 is a novel interactor of Bcr-Abl and possible negative regulator of Bcr-Abl activity and leukemogenesis | I. Kaupe (Vienna) | |
| Glyoxalase-L induction during hypoxia adaptation is a novel target in CML stem Cells | T. Maekawa (Kyoto) | |
| Overexpression and phosphorylation of eLF4E is required for β -catenin activation in blast crisis Chronic Myelogenous Leukaemia | T. Ong (Singapure) | |
| Session 5 | Genomic instability - Chair: J. V. Melo (Adelaide) | |
| 15h15 - 15h30 |
Introducer: Molecular basis of genomic instability |
T. Skorski (Philadelphia) |
| 15h30-15h40 | B-cell mutator AID promotes B lymphoid blast crisis | M. Muschen (Los Angeles) |
| 15h40-15h50 | Mitochondrial origin of intracellular ROS in CML | M. Sattler (Boston) |
| 15h50-16h00 | Hematopoietic stem cell quiescence promotes error prone DNA repair and mutagenesis | E. Passegué (San Francisco) |
| 16h00-16h10 | Alternative NHEJ is a novel therapeutic target in a subset of imatinib resistant CML patiens | F. Rassool (Baltimore) |
| 16h10-16h20 | Results of SNP-arrays in various phases | S. Soverini (Bologna) |
| 16h20-16h30 | Discussion | |
| 16h30 - 17h00 |
Break with poster viewing |
|
| Session 6 | Leukemia stem cells - Chair: C. Eaves (Vancouver) | |
| 17h00 - 17h15 |
Defining and target LSC |
T. Holyoake (Glasgow) |
| 17h15-17h25 | NUP98-HOXA10 expands CML-CP stem cells | I. Sloma (Vancouver) |
| 17h25-17h35 | Effects of IFNα on LSC | M. Essers (Heidelberg) |
| 17h35-17h45 | Smo inhibition to eradicate LSC | G. Martinelli (Bologna) |
| 17h45-17h55 | How CML stem cells escape imatinib | J. Wang (San Diego) |
| 17h55-18h05 | Targeting CML stem/progenitor cells by combining new ABL and JAK inhibitors | X. Jiang (Vancouver) |
| 18h05-18h30 | Discussion | |
| Saturday, September 12, 2009 | ||
| 08h00 - 08h15 |
Plenary presentation: The real role of JAK2-V617F- T. Green (Cambridge) |
|
| Session 7 | Animal models- Chair: F. Frassoni (Genoa) | |
| 08h15 - 08h30 |
Can murine models still be improved? |
R. van Etten (Boston) |
| 08h30-08h40 | Stem cell transformation by BCR-ABL | R. Bhatia (Los Angeles) |
| 08h40-08h50 | Results with stat-5 conditional knockout mice | C. Walz (Boston) |
| 08h50-09h00 | Regulation of CML progression by the cell fate determinant Numb | T. Ito (Durham) |
| 09h00-09h10 | Generation of an in vivo BCR-ABL T315I embryonic stem cell leukemia model | M. Melkus (Poitiers) |
| 09h10-09h20 | Novel molecular pathways in LSC using mouse models | S. Li (Boston) |
| 09h20-09h30 | Discussion | |
| Session 8 | Immunobiology - Chair: R. Hehlmann (Mannheim) | |
| 09h30 - 09h45 |
How and when to use immunotherapy? |
R. Clark (Liverpool) |
| 09h45-09h55 |
Effetcs of TKIs on "normal" immune responses |
K. Rezvani (London) |
| 09h55-10h05 | Expansion of functional pre-existing memory T- cells during treatment | S. Mustjoki (Helsinki) |
| 10h05-10h15 | Ex vivo expanded NK cells to target quiescent LSC | A. Yong (Bethesda) |
| 10h15-10h30 |
Discussion |
|
| 10h30 - 11h15 | Break with poster viewing | |
| Session 9 | Mechanisms underlying resistance to TKIs - Chair: F. Cervantes (Barcelona) | |
| 11h15 - 13h00 | Which mechanisms are important | A. Hochhaus (Jena) |
| 11h30-11h40 | FoxO involvement in CML | D. Cilloni (Torino) |
| 11h40-11h50 |
Changes in miR induced by IM in vivo |
S. Flamant (Vancouver) |
| 11h50-12h00 | MDR polymorphisms | J. Cornelissen (Rotterdam) |
| 12h00-12h10 | Glucocorticoid induced leucine zipper overcomes TKI resistance | B. Quesnel (Lille) |
| 12h10-12h20 | Resistance profile of bosutinib using a high through put sequencing assay | R. Piazza (Milan) |
| 12h20-12h30 | PLK1 as a novel target in CML: overriding TKL resistance with a PLK1 inhibitor | K. Gleixner (Vienna) |
| 12h30-12h40 | Combination therapy and mechanism of resistance to the combined BCR-ABL and pan-aurora kinase inhibitor PHA739358 | S. Balabanov (Hamburg) |
| 12h40-13h00 | Discussion | |
| 13h00 - 14h30 |
LUNCH with poster viewing |
|
| Session 10 |
Panel & poster Discussion - Chair: J. Goldman |
|
| 14h30 - 15h30 | Selected topics from posters | |
| Imatinib induces cisplatin hypersensitivity | W. Aulizky (Stuttgart) | |
| BCR-ABL 1 oncogene down-regulates the expression of OCT1 in CML | A. Bazeos (London) | |
| Development of a high-troughput liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay to measure intracellular level of Imatinib, N-desmethyl-Imatinib and Nilotinib | L. Busque (Montreal) | |
| Loss of LKZF1 or PAX5 simulates human leukemia | R.I. Collins Underwood (Memphis) | |
| Abnormal Ph-negative hematopoiesis in patients responding to TKIs | C. Lobetti (Torino) | |
| Decreased levels of Shp1 promote Ph+ cell survival | C. Quintarelli (Naples) | |
| The functional activity of the OCT-1 protein is predictive of long-term outcome in CP-CML patients treated with Imatinib: A 5 year update of TIDEL data | D. White (Adelaide) | |
| Session 11 |
Clinical results of TKIs - Chair: M. Baccarani (Bologna) |
|
| 15h30 - 15h45 |
Future prospects |
T. Hughes (Adelaide) |
| 15h45-15h55 | IM plus pegylated IFN-α | D. Réa (Paris) |
| 15h55-16h05 | KD mutations during second line TKI therapy | S. Branford (Adelaide) |
| 16h05-16h15 | Factors that determine the optimal of molecular response | D. Marin (London) |
| 16h15-16h25 | Imatinib longterm effects study in CML | C. Gambacorti (Monza) |
| 16h25-16h35 | STIM update | F.-X. Mahon (Bordeaux) |
|
Discussion |
||
| Sunday, September 13, 2009 | ||
| Session 12 |
New therapeutic approaches - Chair: J. Apperley (London) |
|
| 08h30 - 08h45 |
Introducer: Where next? |
J. Cortes (Houston) |
| 08h45-08h55 | Front-line use of dasatinib and nilotinib | G. Rosti (Bologna) |
| 08h55-09h05 | A new inhibitor of T315l | J. Griffin (Boston) |
| 09h05-09h15 | Forskolin of FTY720 for CML in advances phase | D. Perrotti (Columbus) |
| 09h15-09h25 | Inhibiting autophagy | P. Salomoni (Leicester) |
| Discussion | ||
| Session 13 | The next decade - Chair: R. Silver (New York) | |
| 10h00 - 10h15 |
Appropriate endpoints for RCTs with imatinib and newer TKLs |
S. O'Brien (Newcastle) |
| 10h15-10h45 |
Debates: |
|
| 10h45-11h15 | 2. Do we need molecular monitoring for FISH-negative patients? Against - G. Saglio (Bologna) For - C. Schiffer (Detroit) |
|
| What does the future hold? | J. Goldman (London) | |
| Discussion | ||
| 12H00 | End of the meeting | |
